Bavarian Nordic A/S (BAVA.CO) stock: key figures, P/E, revenue and dividend

Health Care · Denmark · ISIN DK0015998017

Price
245.00 DKK
Market cap
19.12 bn DKK
P/E (2025)
13.94
P/S (2025)
3.10
Dividend yield
0.00 %
Net margin
22.28 %
Return on equity (ROE)
10.68 %
Return on assets (ROA)
9.19 %

Bavarian Nordic A/S financials

Fiscal year20242025
Revenue5.72 bn DKK6.17 bn DKK
Gross profit2.82 bn DKK2.92 bn DKK
Operating income1.06 bn DKK1.03 bn DKK
EBIT985.00 m DKK920.00 m DKK
Net income987.00 m DKK1.38 bn DKK
Diluted EPS – continuing operations12.57 DKK17.57 DKK

Full history since 1996, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.